GlassScriptPhysician profile
Jacqueline A Sroka
NPI 1689902777
$2,301.57
in general payments reported to CMS, 2019-2025
26 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.86 · 2023: $52.26 · 2024: $2,022 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $794.26 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $438.12 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $103.60 | 2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $100.12 | 2024 | |
| Mannkind Corporation | $96.31 | 2024 | |
| Antares Pharma, INC. | $88.08 | 2024-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.08 | 2024 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $65.18 | 2024 | Recorlev |
| Beta Bionics, INC. | $64.64 | 2024 | Ilet Bionic Pancreas |
| Abbvie INC. | $62.44 | 2024 | |
| Radius Health, INC. | $53.94 | 2024 | |
| Tandem Diabetes Care, INC. | $52.68 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $46.89 | 2024 | Licart, Tirosint |
| Corcept Therapeutics | $29.72 | 2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $29.07 | 2024 | Strensiq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $26.07 | 2024 | Crysvita |
| Recordati_rare_diseases_inc. | $24.12 | 2024 | Signifor Lar, Isturisa |
| Astellas Pharma US INC | $22.70 | 2024 | Veozah |
| Cequr Corporation | $22.40 | 2024 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $19.93 | 2024 | Nexletol |
| Amgen INC. | $14.91 | 2024 | Evenity, Prolia |
| Medtronic, INC. | $14.86 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.65 | 2023 | NP Thyroid 60 |
| Amryt Pharma Holdings LTD | $13.59 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $13.22 | 2024 | |
| Theracosbio, LLC | $11.99 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Sroka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.